Amgen Under Scrutiny Over Enbrel Marketing

Law360, New York (January 18, 2008, 12:00 AM EST) -- New Jersey’s attorney general has launched a probe into whether Amgen Inc. violated patient confidentiality laws by trying to sell its drug Enbrel and marketing the drug for off-label uses.

New Jersey Attorney General Anne Milgram said Thursday that the state has issued a subpoena to the pharmaceutical company concerning allegations that, in an effort to increase the sale of Enbrel, the company violated patient confidentiality laws and marketed the drug for uses for which it was not approved.

Enbrel, an injectable immunosuppressant, was originally approved...
To view the full article, register now.